BioVie, Inc. (BIVI)
Stock Price: $34.26 USD
-3.25 (-8.66%)
Updated Jan 27, 2021 2:43 PM EST - Market open
| Market Cap | 490.13M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.12M |
| Shares Out | 5.97M |
| EPS (ttm) | -10.97 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $34.26 |
| Previous Close | $37.51 |
| Change ($) | -3.25 |
| Change (%) | -8.66% |
| Day's Open | 36.70 |
| Day's Range | 33.38 - 37.25 |
| Day's Volume | 50,498 |
| 52-Week Range | 7.85 - 42.09 |
News
There are no news available yet.
About BIVI
BioVie, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
| Industry Biotechnology | Founded 2013 |
| CEO Terren S. Peizer | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol BIVI |